UY25823A1 - Derivados de indol y su uso en el tratamiento de la migrana - Google Patents

Derivados de indol y su uso en el tratamiento de la migrana

Info

Publication number
UY25823A1
UY25823A1 UY25823A UY25823A UY25823A1 UY 25823 A1 UY25823 A1 UY 25823A1 UY 25823 A UY25823 A UY 25823A UY 25823 A UY25823 A UY 25823A UY 25823 A1 UY25823 A1 UY 25823A1
Authority
UY
Uruguay
Prior art keywords
treatment
migranes
indol
derivatives
hemesis
Prior art date
Application number
UY25823A
Other languages
English (en)
Inventor
Ronald James Ogilvie
Cristopher Ian Dallman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY25823A1 publication Critical patent/UY25823A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La presente invención proporciona bromohidratos de eletriptán monohidratado de fórmula (I): HBr H2O. Este compuesto es el bromhidrato de eletripán anhidro: 3-((1-metilpirrolidin-2(R)-il)metil)-5-82-fenilsulfoniletil)-1H-indol, estr clasificado como un agonista receptor 5-HTIB/Id y es de particular utilidad en el tratamiento de la migrana, También puede utilizarse para tratar hipertensión, depresión, hemesis, trastornos de alimentación, abusos de fármacos, dolor, cefalea asociada a un trastorno vascular.
UY25823A 1998-11-27 1999-11-29 Derivados de indol y su uso en el tratamiento de la migrana UY25823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
UY25823A1 true UY25823A1 (es) 2001-08-27

Family

ID=10843140

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25823A UY25823A1 (es) 1998-11-27 1999-11-29 Derivados de indol y su uso en el tratamiento de la migrana
UY25825A UY25825A1 (es) 1998-11-27 1999-11-30 Procedimiento para preparar derivados de indol

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25825A UY25825A1 (es) 1998-11-27 1999-11-30 Procedimiento para preparar derivados de indol

Country Status (53)

Country Link
US (2) US20020013358A1 (es)
EP (1) EP1135381B1 (es)
JP (1) JP3777094B2 (es)
KR (1) KR100413739B1 (es)
CN (1) CN1131860C (es)
AP (1) AP2001002149A0 (es)
AR (1) AR024232A1 (es)
AT (1) ATE273300T1 (es)
AU (1) AU754731B2 (es)
BG (1) BG64706B1 (es)
BR (1) BR9915692A (es)
CA (1) CA2352392C (es)
CO (1) CO5150178A1 (es)
CR (1) CR6325A (es)
CU (1) CU23269A3 (es)
CZ (1) CZ295472B6 (es)
DE (1) DE69919388T2 (es)
DK (1) DK1135381T3 (es)
DZ (1) DZ2948A1 (es)
EA (1) EA003551B1 (es)
EE (1) EE04914B1 (es)
ES (1) ES2224701T3 (es)
GB (1) GB9825988D0 (es)
GC (1) GC0000113A (es)
GE (1) GEP20043183B (es)
GT (1) GT199900202A (es)
HK (1) HK1042898B (es)
HN (1) HN1999000196A (es)
HR (1) HRP20010398B1 (es)
HU (1) HUP0105308A3 (es)
ID (1) ID28802A (es)
IL (1) IL141663A (es)
IS (1) IS2238B (es)
MA (1) MA26708A1 (es)
MY (1) MY124078A (es)
NO (1) NO320798B1 (es)
NZ (1) NZ510055A (es)
OA (1) OA11671A (es)
PA (1) PA8485701A1 (es)
PE (1) PE20001299A1 (es)
PL (1) PL194503B1 (es)
PT (1) PT1135381E (es)
RS (1) RS50002B (es)
SI (1) SI1135381T1 (es)
SK (1) SK285774B6 (es)
SV (1) SV1999000204A (es)
TN (1) TNSN99221A1 (es)
TR (1) TR200101493T2 (es)
TW (1) TWI246512B (es)
UA (1) UA68402C2 (es)
UY (2) UY25823A1 (es)
WO (1) WO2000032589A1 (es)
ZA (1) ZA200102681B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
WO2008137134A2 (en) * 2007-05-01 2008-11-13 Teva Pharmaceuticals Usa, Inc. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
DK0592438T5 (da) 1990-10-15 1999-12-06 Pfizer Inc. Indolderivater
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
DE69802097T2 (de) 1997-07-03 2002-03-14 Pfizer Ltd Eletriptanhemisulfat und kaffein enthaltende pharmazeutische zusammenstellungen

Also Published As

Publication number Publication date
HK1042898B (zh) 2004-10-08
AR024232A1 (es) 2002-09-25
AU6225399A (en) 2000-06-19
IS5868A (is) 2001-02-27
EE200100285A (et) 2002-08-15
CN1328554A (zh) 2001-12-26
DE69919388D1 (de) 2004-09-16
BG64706B1 (bg) 2005-12-30
ES2224701T3 (es) 2005-03-01
ATE273300T1 (de) 2004-08-15
ID28802A (id) 2001-07-05
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
DE69919388T2 (de) 2005-09-29
CU23269A3 (es) 2008-04-09
US20050131237A1 (en) 2005-06-16
EP1135381A1 (en) 2001-09-26
CN1131860C (zh) 2003-12-24
EA003551B1 (ru) 2003-06-26
HRP20010398B1 (en) 2004-12-31
JP3777094B2 (ja) 2006-05-24
SK6992001A3 (en) 2002-01-07
PE20001299A1 (es) 2000-12-01
NZ510055A (en) 2004-11-26
PT1135381E (pt) 2004-10-29
MY124078A (en) 2006-06-30
TWI246512B (en) 2006-01-01
HK1042898A1 (en) 2002-08-30
CA2352392C (en) 2006-01-24
DZ2948A1 (fr) 2004-03-15
DK1135381T3 (da) 2004-11-15
US20020013358A1 (en) 2002-01-31
SV1999000204A (es) 2000-10-16
AU754731B2 (en) 2002-11-21
MA26708A1 (fr) 2004-12-20
BG105539A (en) 2001-12-29
IS2238B (is) 2007-05-15
NO20012584L (no) 2001-07-27
HUP0105308A2 (hu) 2002-05-29
UY25825A1 (es) 2000-08-21
CA2352392A1 (en) 2000-06-08
GB9825988D0 (en) 1999-01-20
CZ295472B6 (cs) 2005-08-17
RS50002B (sr) 2008-09-29
SI1135381T1 (en) 2004-10-31
HN1999000196A (es) 2005-11-26
AP2001002149A0 (en) 2001-06-30
CR6325A (es) 2008-07-02
KR20010080594A (ko) 2001-08-22
UA68402C2 (en) 2004-08-16
YU18801A (sh) 2003-07-07
US7238723B2 (en) 2007-07-03
GT199900202A (es) 2001-05-19
BR9915692A (pt) 2001-08-14
TR200101493T2 (tr) 2002-02-21
ZA200102681B (en) 2002-07-02
IL141663A0 (en) 2002-03-10
PA8485701A1 (es) 2000-09-29
CZ20011839A3 (cs) 2001-10-17
JP2002531449A (ja) 2002-09-24
NO320798B1 (no) 2006-01-30
IL141663A (en) 2004-05-12
SK285774B6 (sk) 2007-08-02
NO20012584D0 (no) 2001-05-25
EE04914B1 (et) 2007-10-15
HUP0105308A3 (en) 2003-01-28
PL347928A1 (en) 2002-04-22
EA200100297A1 (ru) 2001-08-27
HRP20010398A2 (en) 2002-06-30
CO5150178A1 (es) 2002-04-29
PL194503B1 (pl) 2007-06-29
GEP20043183B (en) 2004-02-25
WO2000032589A1 (en) 2000-06-08
TNSN99221A1 (fr) 2005-11-10
OA11671A (en) 2005-01-12
KR100413739B1 (ko) 2004-01-03

Similar Documents

Publication Publication Date Title
UY25823A1 (es) Derivados de indol y su uso en el tratamiento de la migrana
BR9206810A (pt) Derivados de indol
DE60018274D1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
GB0504828D0 (en) Therapeutic agents
TR200102161T2 (tr) Pirazino(aza)indol türevleri.
FI954944A0 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
HK1092135A1 (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo [3.2.0]heptane is an effective analgesic agent
ATE218566T1 (de) Indol derivate als 5-ht1 agoniste
EE05305B1 (et) Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
AU5614198A (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
YU29496A (sh) So pirolidinil metil indola
Wheeler Naratriptan prophylaxis of transformed migraine or hemicrania continua?
EA200301221A1 (ru) Лечение расстройств с гиперактивностью и дефицитом внимания
ATE224388T1 (de) Indolderivate zur behandlung von migräne
NZ508292A (en) Treatment of migraine symptoms with ibuprofen and salts thereof

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090309